Beyond the Buzzword: AI Strategies for Accelerating Clinical Research

Rebecca Clyde, CEO, Botco.ai | Derek Ansel, Vice President, Therapeutic Strategy Lead, Rare Disease, Worldwide Clinical Trials

December 4, 2025 | 11:00am PST

Join Botco.ai CEO Rebecca Clyde and guest expert Derek Ansel, Vice President and Therapeutic Strategy Lead for Rare Disease at Worldwide Clinical Trials, for a practical discussion on how AI can speed evidence generation and clinical operations. This session is ideal for clinical operations leaders, biotech and pharma sponsors, CRO teams, and data and innovation professionals who want clear, actionable next steps.

What you will learn:

Define AI use across the biotech industry.
Provide a framework for when and how to incorporate AI into clinical trials.
Uncover areas where AI is relatively easy to use within your current corporate environment.
Share real-world examples of how rare-disease focused companies are leveraging AI to expedite drug development

SPEAKERS

Rebecca Clyde | CEO Botco.ai

Rebecca Clyde is an accomplished business leader with unique expertise in marketing automation and company building. Prior to Botco.ai, she founded Ideas Collide, an Inc. 5000 digital agency now in its 20th year serving Fortune 500 companies including major healthcare brands like Blue Cross Blue Shield Arizona and Banner Health. She was previously a digital strategist at Intel and holds an MBA from Arizona State University.

Derek Ansel | Vice President, Therapeutic Strategy Lead, Rare Disease, Worldwide Clinical Trials

Derek Ansel, MS, LCGC, has worked in clinical research for more than 13 years with a focus almost exclusively on rare and pediatric diseases, including neurodevelopment disorders, non-malignant hematology, autoimmune diseases, metabolic disorders, movement disorders, and other genetic conditions. At Worldwide, he leads and supports corporate initiatives within rare and pediatric diseases, including genetic disorders, and cultivates relationships with over 120 patient-focused advocacy organizations.

About Botco.ai

Botco.ai is the Enterprise AI Agent Platform purpose-built for organizations that need to engage customers through intelligent, reliable, and secure AI conversations. The platform enables enterprises to seamlessly create, securely deploy, and easily manage autonomous AI agents using a no-code development environment (IDE) and retrieval-augmented generation (RAG) technology. Trusted by leading healthcare, behavioral health, and pharmaceutical organizations, Botco.ai empowers businesses to convert conversations into revenue, reduce operational costs, and improve customer satisfaction. Recognized as “Most Outstanding Startup” by the Arizona Innovation Challenge and winner of the TiE50 and ACA Best SaaS Platform awards, Botco.ai is redefining how enterprises engage with their audiences through agentic AI.To learn more, visit www.botco.ai.